Franz Humer Leaves Glaxo

5 December 1994

- Franz Humer, a director of the board at Glaxo, has resigned to "take up a senior appointment in the international pharmaceutical industry next year." According to press reports in the UK, Swiss company Roche has refused to comment whether Mr Humer will be joining as head of its pharma operations, a position which became vacant last month when Peter Simon resigned to pursue other interests. Mr Humer, who is prohibited from taking a job with a rival company for six months, had been tipped to take over from Ernest Mario as chief executive but this position went to Sir Richard Sykes, research and development director.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight